

Key Investor Information

This document provides you with key investor information about this fund. It is not marketing material. The information is required by law to help you understand the nature and the risks of investing in this fund. You are advised to read it so you can make an informed decision about whether to invest.

J. Lamarck Biotech – Class B (LU0574994512) A Sub-Fund of “SELECTRA INVESTMENTS SICAV” The fund is managed by TMF FUND MANAGEMENT S.A.

Objectives and Investment Policy

The main objective of the Sub-Fund is to profit from increasing share prices in the biotechnology sector. The focus is on mature top tier pharmaceutical biotech companies and companies with interesting pipeline of products in development in a single or numerous markets, like NASDAQ or NYSE.

The followed investment policy will enable the Sub-Fund to increase overall return relative to the NASDAQ Biotech Index by active stock selection of companies, offering the most promising technology platform.

To achieve this investment objective, the Sub-Fund will take long positions in these shares issued mainly by US issuers, and only secondarily by European or Asian issuers.

The Sub-Fund does not consider the adverse impacts of investment decisions on sustainability factors in line with Article 4.1 (b) of the Regulation (EU) 2019/2088 (SFDR) and considers sustainability risks and Principal Adverse Impacts (PAIs) as not relevant. The Sub-Fund is neither in scope of 8 nor of Article 9 of the SFDR. The investments underlying this financial product do not take into account the EU criteria for environmentally sustainable economic activities.

The Sub-Fund will not invest in derivatives (such as single stock futures, index futures, warrants or options) to meet the Sub-Fund's investment objective but it may use financial derivative instruments for the purpose of hedging currency risks only.

The Sub-Fund may invest up to 10% of its total net assets in shares/units of UCITS and/or other UCIs (including ETF).

This Sub-Fund is best suited for investors who seek to invest worldwide in shares of companies active in the biotechnology sector.


The Sub-Fund may not be appropriate for investors who plan to invest with a short-term horizon (<5 years).

You will not receive any dividend from the Sub-Fund. The dividends received by the Sub-Fund will be reinvested in it.

You can redeem your shares daily during Luxembourg business days, before (cut-off) 17:00 pm (Luxembourg time).

For a deeper understanding of the main features and implications of the investment in the Sub-Fund, please refer to the dedicated annex to the prospectus.

Risk and Reward Profile



Historical data, such as is used in calculating the synthetic indicator, may not be a reliable indication of the future risk profile of the Sub-Fund. The risk and reward category shown is not guaranteed to remain unchanged and that the categorisation of the Sub-Fund may shift over time. The lowest risk and reward category does not mean a risk free investment.

Due to the fact that the Sub-Fund invests in a specific and high-volatile market sector (biotechnology), the risk indicator is consequently high (6). However, the risk category shown is not guaranteed and may shift over time while the lowest category does not mean “risk free”.

Besides, you must be aware that historical data is not a reliable indication of the future risk profile of the Sub-Fund. Please note the following risks are materially relevant to the Sub-Fund and are not adequately captured by the indicator:

- Liquidity risk: reduced liquidity means there are insufficient buyers or sellers to allow the Sub-Fund to sell or buy investments readily;
- Concentration risk: this risk is considered as moderated;
- Market risk: Price trends are determined mainly by financial market trends and by the economic development of the issuers, who are themselves affected by the overall situation of the global economy and by the economic and political conditions prevailing in each country. Market risk ranges from low to medium-high according to assets allocation.


For further information concerning the risks of your investment, we recommend you to consult the sales Prospectus of the Sub-Fund. It is available at the registered office of the Company and on the website www.selectrasicav.com.

Charges

One-off charges taken before or after you invest	
Entry charge	3.00%
Exit charge	0.00%
Charges taken from the fund over a year	
Ongoing charge	3.92%
Charges taken from the fund under certain specific conditions	
Performance fee	The Sub-Fund is subject to a Performance Fee of 20% with High Water Mark, taking subscriptions and redemptions into account and payable annually.

Such charges, that you bear as an investor, are used for the operation of the Sub-Fund, including its marketing and distribution. You must be aware that they reduce the potential of the return of your investment. The entry and exit charges indicated are maximum amounts. The percentages may be lower in various cases. Your shares in this Sub-Fund may be exchanged for shares in other Sub-Funds of the Company. A conversion fee of 1% will be charged. The ongoing charges are based on actual figures over the last twelve months and could vary depending on the assets under management. Also, the figure may vary from year to year and will be updated within 12 months from the Sub-Fund launch. The ongoing charges do not include transaction costs. For further information concerning the charges on your investment, we recommend you to read the Prospectus of the Fund. It is available at the registered office of the Company and on the website www.selectrasicav.com.

Past Performance



Past performance has limited value as a guide to future performance.

The chart shows the Sub-Fund's annual performance in EUR for each full calendar year over the period displayed in the chart. It is expressed as a percentage change of the Sub-Fund's net asset value at each year-end.

The Sub-Fund has been launched on 24 January 2011.

This share class has been launched on 26 January 2011.

Performance is shown after deduction of ongoing charges. Any entry/exit charges are excluded from the calculation.

The reference currency of the Sub-Fund is EUR.

The Sub-Fund does not track any benchmark.

Practical Information

Depository Bank

QUINTET PRIVATE BANK (EUROPE) S.A.

Additional information and publication of the net asset value

Further information about the Sub-Fund and copies (in English and Italian) of its latest valid prospectus, annual and semi-annual reports, as well as the most recent prices may be obtained free of charge from the registered office of SELECTRA INVESTMENTS SICAV and on the website www.selectrasicav.com.

Remuneration Policy

Details of the latest remuneration policy of TMF Fund Management S.A. can be found [here](#). This policy includes details of how remuneration and benefits are calculated, the identity of persons responsible for awarding the remuneration and benefits, including the composition of the remuneration committee. A paper copy will also be made available free of charge upon request.

Segregation

This Sub-Fund is part of SELECTRA INVESTMENTS SICAV. Under Luxembourg law, there is segregated liability between sub-funds, meaning that the assets of this Sub-Fund will not be available to meet a claim of a creditor or another third party made against another sub-fund.

Switching

You have the right to switch all or part of your Shares in the Sub-Fund in accordance with the "Conversion of Shares" section of the prospectus and as described in detail in the dedicated annex to the prospectus.

Liability

TMF FUND MANAGEMENT S.A. may be held liable solely on the basis of any statement contained in this document that is misleading, inaccurate or inconsistent with the relevant parts of the prospectus for the Sub-Fund.

Taxation

The Fund is subject to Luxembourg tax legislation. Depending on your domicile, this may have an effect on your investment.

Specific information

This Sub-Fund consists of multiple Share Classes. SELECTRA INVESTMENTS SICAV consists of multiple Sub-Funds. The Prospectus and the reports are however drawn up for the SICAV as a whole.